维持性血液透析患者肌少症与衰弱的临床研究进展  

Clinical research progress of sarcopenia and frailty in maintenance hemodialysis patients

作　　者：何茂芯 袁怀红 杨玉洁 余少斌[2] 付平[2] HE Maoxin;YUAN Huaihong;YANG Yujie;YU Shaobin;FU Ping(Department of Nephrology,West China Hospital,Sichuan University/West China School of Nursing,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Department of Nephrology/Kidney Research Institute,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院肾脏内科/四川大学华西护理学院,成都610041 [2]四川大学华西医院肾脏内科/肾脏病研究所,成都610041

出　　处：《华西医学》2022年第11期1720-1725,共6页West China Medical Journal

基　　金：四川大学华西医院学科发展1·3·5工程项目(ZYGD18027)。

摘　　要：维持性血液透析患者肌少症和衰弱的发生率较高,且常有共病的现象,易导致患者发生更多的并发症,从而增加患者的住院率,降低患者的生活质量。该文就维持性血液透析患者的肌少症及衰弱的定义、生理机制、发生率及诊断、二者关系、治疗策略等多方面进行综述,目的是更好地预防和干预患者肌少症及衰弱的发生并为其防治提供借鉴。The incidence of sarcopenia and frailty in maintenance hemodialysis patients are high,and there are often comorbidities,which easily lead to more complications,thus increasing the hospitalization rate and reducing the quality of life of patients.This article reviews the definition,physiological mechanism,incidence and diagnosis,relationship and treatment strategies of sarcopenia and frailty in maintenance hemodialysis patients,in order to better prevent and intervene the occurrence of sarcopenia and frailty and provide a reference for prevention and treatment.

关 键 词：维持性血液透析 肌少症 衰弱 

分 类 号：R692.5[医药卫生—泌尿科学] R685[医药卫生—外科学]